



Covid-19 Overview

Sonawane GA, Vikas B Gawali, VV Pande* and Kardile GN

Department of Pharmacy, NN Sattha College of Pharmacy, India

*Corresponding Author: VV Pandey, Department of Pharmacy, NN Sattha College of Pharmacy, India.

DOI: 10.31080/ASMI.2022.05.1065

Received: March 14, 2022

Published: April 26, 2022

© All rights are reserved by VV Pande., et al.

Abstract

In early January 2019, an until that time undiscovered coronavirus, nowadays recognized as the corona virus 2019, arose from Wuhan, China, and spread worldwide, causing an enormous outbreak in many Chinese cities, including Thailand, Philippines, Republic of Korea, Japan, Viet Nam, United States, and our region. The disease is formally named as Coronavirus Disease-2019. The Taiwan CDC and Ministry of Health named it Severe Pneumonia with Novel Pathogens on January 15, 2019, and it is a fifth-group notifiable contagious disease. COVID-19 is also known as a zoonotic infection with a low to reasonable mortality risk (projected at 2-5%). It travels to Person-to-person can occur by droplet or contact transmission, hitting first-line worker's healthcare at hazard if infection controlling is laid-back or if satisfactory special shielding kit is (PPE) unavailable. There is currently no definitive cure for COVID-19, but numerous therapies are being studied. Physicians must be mindful of the mobile or touch history of patients with well-matched signs to quickly distinguish patients and escape further dissemination.

Keywords: Corona; Diagnosis; Symptoms; Treatment

Introduction

The Wholesale Huanan Seafood Market in Wuhan of Hubei, China, faced an eruption of a mistrustful pneumonia marked by fever, dry cough, nausea, and alternating gastrointestinal symptoms in late December of the year 2019 [1]. The initial outbreak was announced in the market in December 2019 and affected about 66 out of a hundred of the workers there. The business was fold on January 1, 2020, following the declaration of an epidemiologic warning by the resident health consultant on December 31, 2019. Thousands of residents in China, counting several sticks and cities like Beijing and Shanghai, were exaggerated by the disease's speedy spread in the next month (January) [2]. In prior, the epidemic spread to Thailand, Japan, the Republic of Korea, Vietnam, Germany, the United States, and Singapore. On January 21, 2019, the first instance in our country was recorded. As of February 6, 2020, a total of 28,276 confirmed cases and 565 deaths universally were reported by WHO, disturbing at least 25 countries [3].

The eruption's pathogen was previously revealed as a unique beta-coronavirus known as 2019 unique coronavirus (2019-nCoV), which triggered back memoirs of the 17-year-old thrilling acute respiratory syndrome (SARS-2003, prompted by some other beta-coronavirus). In 2003, a new coronavirus, the source of a unidentified pneumonia, was identified in southeast China, definitely Guangdong province, and was assigned the name SARS coronavirus, confirming Koch's theory [4]. The virus's death proportion was calculated to be among 10% and 15% [5,6]. Health services have evolved over time, then no effective cure or injection for SARS is currently available. The finding of a new coronavirus endemic in the Middle East in 2012 has confident correspondences to the 2003 outbreak [7]. Equally they caused by coronavirus, but MERS is believed to be transmitted by the dromedary camel, with a impermanence rate of up to 37% [5]. Equally SARS and MERS have generic initial clinical signs, with the widely held of patients giving with fever and respiratory indications. Undefended hospital workers

who are exposed to patients' droplets or arise into interaction with them are at danger of being tainted and developing nosocomial infections [2,6]. To prevent the virus from spreading further, a vast number of countries have adopted social distancing and lockout measures. We would study our existing understanding of COVID-19 and suggest the fundamental cause to understand the symptomatology's heterogeneity, with a special emphasis on the differences between children and adults.

Pathophysiology

Epidemiological data

So far, a vast number of articles have been reports focused on China's experiences. COVID-19 cases were mainly seen in the aged at the start of the epidemic [8]. As the epidemic progressed, the number of cases for older people increased, but there was also an uptick among children under the age of 18 years. The number of macho patients was greater at first, but there was no substantial sexual category gap as the amount of cases grew. The estimated time for incubation was 5.2 days. A total of 2.3 percent of cases resulted in death [9,10]. The threat issues for in-hospital demise were analysed using evidence from two Wuhan hospitals. The multi-variable study showed that older age, a greater sequential organ miscarriage evaluation (SOFA) score, and d-dimer > 1 g/mL on admission were all danger factors [11]. The involvement of coronary heart disease, diabetes, and hypertension were also discussed and recommendations in the invariable study. The largest of COVID-19 patients expired from multi-organ collapse, as lung inability, tremor, and ARDS were seen in 94 percent, 81 percent, and 74 percent of cases, respectively, in a Wuhan study of 85 fatal COVID-19 patients with a average age of 65 years [12]. High d-dimer stages, fibrinogen, and a elongated thrombin period were seen in serious diseases, which corresponded to the high incidence of multi-organ failure [13]. SARS-CoV-2 has spread everywhere the world since the epidemic in China. The United States has the major registered number of COVID-19 patients as of primary April 2020, followed by Spain, Italy, Germany, France, and China. The epidemic of China had a major impact on Italy. As in the Chinese series, the mortality rate was higher in the elderly population. According to an Italian survey, the case-casualty rate was 7.2 percent [10,14], which was 3 times greater than the Chinese figure. Though its case casualty rate for patients aged 70 and up was highest in Italy, it was very close in both countries among the ages of 0 and 69. The increased mortality in Italy was partly described by the socioeconomic status, as 23 out of a hundred of Italians were 65 yrs or older. Data from

the United States and other nations is accessible in a variety of services [15]. In the near future, we hope to hear more about individual countries' perspectives. Since the start of the epidemic, the fraction of children among COVID-19 patients was negligible. According to information from the Chinese Center for Disease Control and Prevention (China CDC) from February 2020, children below the age of 10 and those between the ages of 11 and 19 accounted for 1% of all cases [9]. Given that this age range accounts for 20% of the generally population, there could be a lower incidence of COVID-19 in the pediatric age group. However, since infants have less signs, this could be an overstatement of the real occurrence in the pediatric population. Due to the Chinese Holiday Season, schools in China were cancelled for the majority of the outbreak, which may have led to less exposure among children. Conferring to the China CDC, 4.4 percent, 50.9 percent, 38.8 percent, and 5.9 percent of COVID-19 paediatric patients were reported as symptomless, minor, medium, or extreme, accordingly [16]. The definition of symptomless, minor, modest, undecorated and critical is shortened in table 1.


Type of Patients	Symptoms
Asymptomatic Patient	COVID nucleic acid test resulted in a positive result. The chest imaging is normal and there are no health complications or signs.
Mild Patients	Fever, headache, myalgia, cough, sore throat, runny nose, sneezing) or intestinal symptoms (nausea, vomiting, stomach pain, diarrhoea) are all symptoms of an acute upper respiratory tract infection.
Moderate Patients	Pneumonia (fever, cough) with no apparent hypoxemia and lesions on chest CT.
Severe Patients	Pneumonia with hypoxemia (SpO ₂ < 92%)
Serious Patients	Tremor, encephalopathy, myocardial injury, cardiac miscarriage, coagulation dysfunction, and acute kidney damage are also potential signs of acute respiratory distress syndrome (ARDS).

Table 1: Classification of COVID-19 patients.

Appliance of SARS-CoV-2 invasion into human host cells

Covid virus are 30 kb enclosed positive-sense single-stranded RNA viruses with a single stranded RNA genome. They affect a widespread number of animal crowds [17]. Grounded on their ge-

nomic composition, they are largely classified into four generally α , β , γ , and δ . Coronaviruses are solitary spread to humans [18]. Human coronaviruses, such as 229E and NL63, are coronaviruses that source the common cold and croup. Coronaviruses, to the contrary, include SARS CoV, Acute Breathing syndrome like sars coronavirus and MERS-CoV, and SARS-CoV-2. There are five stages in the virus's life span with the host.



Viruses invade host cells via endocytosis or membrane fusion after binding to host receptors (attachment) (permeation). Viral RNA joins the nucleus for duplication the viral content is get released into the host or human cell Viral proteins are made from viral mRNA (biosynthesis). Then, after growth and development, new viral particles are created and distributed. Spike (S), sheath (M), envelop (E), and nucleocapsid (N) are the four protein complexes found in Coronaviruses (N) [19]. Spear is a transmembrane trimetric glycoprotein that overhangs since the viral superficial and panels coronavirus variety and host tropism. Spike is finished up of two practical subunits: S1 is in control of attaching to the host cell receptor, while S2 is in control of fusing the viral and cellular tissues. SARS-CoV has remained displayed to take a well-designed receptor in the arrangement of angiotensin transforming enzyme 2 (ACE2) [30]. The spike for SARS-CoV-2 also bound to ACE2, conferring to functional and structural study [20-22]. The expression of

ACE2 was observed to be elevated in the lungs, heart, ileum, kidneys, and bladder [23]. On the epithelial cells of the lungs, ACE2 was highly expressed. More research is needed to determine if SARS-CoV-2 binds to another target. The spike protein is protease cleaved after SARS-CoV-2 binds to the host protein. A dual-step progressive protease cleavage model for activating SARS CoV and MERS-CoV spike protein was suggested, comprising of priming cleavage at the S1/S2 cleavage site and activation cleavage at the S'2 site, which is contiguous to a fusion peptide within the S2 subunit [24,25]. S1 and S2 receptor persist non-covalently attach after cleavage at the S1/S2 joint junction, and the distal S1 subunit helps in the perfusion maintenance of the membrane-anchored S2 receptor [21]. Subsequent joint at the S'2 site, the spike is apparently allowed for membrane combination by permanent accurate variations. The coronavirus spike is distinctive between viruses in that it be able to joined and triggered by a number of proteases [26]. The appearance of a furin joint site ("RPPA" series) at the S1/S2 site separates SARS-CoV-2 from other coronaviruses. In comparison to SARS-CoV spike, which was integrated into assemblage devoid of cleavage, the S1/S2 site of SARS-CoV-2 was fully cleaved through biogenesis [21]. Further proteases, such as transmembrane protease serine 2 (TMPRSS2) and cathepsin L, were able to cleave the S1/S2 location [25-27], Furin's widespread expression kinds this virus extremely pathogenic.

Host response to SARS-CoV-2

Infection caused person with SARS-CoV-2 have marks that vary from reasonable to extreme respiratory letdown with numerous organ failure. Computer tomography is a form of computerized tomography that uses a [24] scan, Even in asymptomatic patients, pulmonary ground glass opacification can be observed typically [28]. Since ACE2 is heavily distributed in the alveolar space on the apical sideways of lung epithelial cells [29,30], This virus has a good chance of infecting and killing them. This is associated with the fact that initial lung damage often manifested in the proximal trachea. Innate immunity in the airway is made up of alveolar macrophages, epithelial cells, and (DCs) dendritic cells [31]. DCs are found below the epithelium. On the epithelium's anterior edge Macrophages are found. Until adaptive immunity is active, macrophages and DCs act as inborn immune cells, fighting viruses.

In extreme infections, thrombosis and pulmonary embolism have been witnessed in prior to respiratory signs. This is associated with the observation that serious diseases have elevated d-dimer and fibrinogen ranks. The endothelium has many features,

including vasodilator, fibroplasia, and anti-aggregation. Since the endothelium is active in thrombotic control [32], Endothelial destruction is most likely the cause of hypercoagulable profiles found in serious diseases. ACE2 is also stated by endothelial cells [33,34]. Endothelial cells account for one-third of all lung cells [35]. Endothelial damage induces microvascular permeability, which may assist viral penetration.

New variants of Covid-19

Viruses are repeatedly developing due to evolution, and novel virus kinds are anticipated to emerge over time. Rarely, new deviations seem and then disappear. New versions look and survive at other stages. Several strains of the COVID-19 virus have been found in the US and around the world since this pandemic. COVID-19 is produced by a virus that has many differences that are spreading everywhere the world. The United Kingdom (UK) identified a variant called B.1.1.7 with a great number of mutations in the fall of 2020.

- Related to other variants, this one spreads more readily and rapidly. Specialists in the UK stated in 2021 January that this alternate could be related to an elevated threat of death as associated to other variant viruses, even though extra research is prerequisite to provide this result. It has subsequently been exposed in an extent of nations all round the world. This version was revealed for the primarily in the United States at the completion of December 2020.
- Separately from B.1.1.7, another version recognized as B.1.351 seemed in South Africa. B.1.351 was discovered in early 2020 October and shares definite alterations with B.1.1.7. This version has been linked to cases in the United States as of the end of 2021 January.
- A variant known as P.1 was discovered in passengers from Brazil who were checked during routine screening at a Japanese airport in early January in Brazil. This form has a number of supplementary transformations that could mark it more problematic for antibodies to detect it. This variety was exposed for the first time in the USA at the end of January 2021.

These alternates tend to blowout relatively quickly and efficiently than other alternatives, possibly prominent to a spike in COVID-19 belongings. A rise in the amount of patients would carry

more burden on health-care facilities, subsequent in more hospital admissions and even more deaths.

Up to now, studies recommend that antibodies produced through vaccination with presently approved vaccines identify these variants. This is being carefully inspected and more studies are happening.

To boundary the spread of the virus that reasons COVID-19 and protect public health, strict and improved obedience with public health justification policies such as vaccination, bodily separation, mask use, hand sanitation, isolation, and separation is needed [35].

Sign and symptoms

Primary symptoms involved fever (98 percent), cough (76 percent), myalgia or fatigue (44 percent), sputum development (28 percent), headache (8 percent), hemoptysis (5 percent), and diarrhoea (5 percent) in the first study of 41 patients reported to have COVID-19 in Wuhan, China (3 percent). Dyspnea occurred in 55% of sufferer, with ARDS occurring in 29% of those who advanced. A total of 13 (32%) patients were confessed to the ICU, with 6 (15%) of them dying [36]. A consequent description of 138 patients from Wuhan noticed that 98.6% of the patients had flu, 69.6% had exhaustion, and 59.4% had a dry cough. In that group, 36 patients (26%) received ICU treatment, and six patients (4.3%) expired [36].

In a wider, multi-organized study of 1099 sufferer with research lab validated COVID-19 across China, it was discovered that 88.7% of sufferer experienced fever while their hospital stay. Cough was the second maximum frequent condition (67.8 percent). Nausea or vomiting (5 percent) and diarrhoea were less common (3.8 percent). Upper respiratory problems are rare, with just 13.9 percent of patients reporting sore throat and 4.8 percent reporting nasal inflammation. Five percent of the patients were taken to the rigorous care unit, 2.3 percent received artificial ventilation, and 1.4 percent died [37]. Multiple recent experiments have discovered chemosensory sanitization connected with COVID-19, which were not previously published [38,39], According to one study, up to 85.6 percent and 88 percent of people suffer from olfactory and gustatory disorder, specifically [40]. In fact, recent evidence reveals that the asymptomatic carrier levels varies from 17.9% to 21.7 percent [41]. Lymphocytopenia (83.2%), thrombocytopenia (36.2%), and

leukopenia were the most common laboratory deviations (33.7 percent) [37].

Diagnosis

Polymerase chain reaction and serology

COVID-19 is typically diagnosed with a nasal swab and polymerase chain reaction examination. Medical, research laboratory, and imaging discoveries can furthermore be applied to render a reasonable diagnosis due to the high incidence of false undesirable test results in SARS-CoV-2 PCR analysis of nasal swabs.

Serology and Polymerase Chain Reaction SARSCoV-2 RNA analysis using reverse transcription polymerase chain response from respiratory models (e.g., nasopharynx) is the gold procedure for diagnosis. Conversely, the intensity of testing varies depending on whether it is performed in relative to radiation. Sensitivity was reported to be 33 percent 4 days after disclosure, 62 percent on the day of indication beginning, and 80 percent 3 days later initial diagnosis, according to one modelling report [42,43]. The suitability of the specimens selection method, time from contact, and sample source are all variables that lead to false-negative test findings. Lower respiratory samples are more susceptible than upper respiratory samples, such as bronchoalveolar lavage fluid. Bronchoalveolar lavage fluid specimens had the maximum optimistic rates of SARS-CoV-2 PCR testing findings (93 percent) amongst 1070 specimens acquired from 205 patients with COVID-19 in China, directed by sputum (72 percent), nasal swabs (63 percent), and pharyngeal wipes (63 percent) (32 percent) [42]. SARS-CoV-2 can be applied in faeces as well, but not in urine. Saliva may be an alternate specimen source that involves a smaller amount PPE and fewer swabs, but it needs to be validated further [44].

Several serological tests can also be used to decide the diagnosis and evaluation of vaccine reactions [45]. However, since not all antibodies formed in reaction to infection are neutralising, the existence of anti-bodies cannot confer immunity. Second contaminations with SARS-CoV-2 are unexplained, as is the frequency with which they occur. If the existence of an antibody alters resistance of future infections. It's unclear when infection occurs or how long anti-body defence lasts. IgM antibodies are detected within 5 days of diagnosis, with higher IgM levels in weeks 2-3, and an IgG reaction appears 14 days after sign onset [45,46]. Antibody titers that are higher Which is more likely in cases of more serious illness. 66 Point-of-care analyses and high-output enzyme immunoassays are among the serological tests available. Test efficiency, precision, and validity, on the other hand, are all variable [47].

Imaging

COVID-19 is characterised by diffuse, peripheral ground-glass opacities on chest calculated tomographic imaging [48]. Ill-defined edges, air broncho grams, broader abnormal inter lobular or septal swelling, and condensing of the neighbouring pleura describe ground-glass opacities. Timely in the illness, chest figured tomographic imaging studies in 15% of people and chest radiograph observations in 40% of people may be common [49]. Abnormalities will progress quickly in the first two weeks later symptom initiation, then eventually fade away. The diagnostic utility of chest computed tomographic imaging for COVID-19 is reduced because the results are general and correlate with other infections. Few patients with SARS-CoV-2 infection confirmed by polymerase chain reaction have typical computed tomographic imaging outcomes, while in others, irregular chest figured tomographic imaging findings consistent with COVID-19 appear days earlier SARS-CoV-2 RNA is detected [48].

Treatment

More than 75% of COVID-19 sufferer in hospitals need additional oxygen treatment. Intense high-run nasal cannula oxygen can be used by patients who do not re-join to traditional oxygen remedy. Lung- defensive ventilation with low tidal bulks (4-8 mL/kg, expected body weight) and plateau force less than 30 mg Hg is prescribed for patients needing intrusive automated aeration. In addition, prone arranging, a advanced positive end-expiratory density approach, and short-period neuro muscular barrier with cisatracurium or other muscle relaxants may enable oxygenation. Despite the fact that some COVID-19-related respiratory miscarriage patients have great lung defiance, Lung-protective ventilation is also going to be helpful to them. Lung compliance has been revealed to be comparable across ARDS cohorts, and even patients using higher obedience have benefited from lower tidal volume techniques. Since certain patients take usual work of inhalation but extreme hypoxemia, the threshold for intubation in COVID-19-related respiratory failure is debatable. Because of the practical difficulties of transporting patients to an flying separation room and get into personal defensive apparatus prior to intubation, "earlier" intubation makes for a more regulated intubation process. Hypoxemia in the lack of respiratory failure, on the other hand, is well tolerated, and patients will be able to work without the use of artificial ventilation. Early stenting levels can result in the unnecessary use of artificial ventilation in some patients, leading them to additional risks. There is presently little data to make judgements on intubation timing.




Figure 2: Treatment on Covid-19.

According to retrospective findings, about 8% of hospitalized COVID-19 patients develop a bacterial or fungal parallel infection, but up to 72% are diagnosed with broad-spectrum antibiotics. In the absence of further information, it may be advisable to refrain from using antibacterial drugs in COVID-19 patients and save them for individuals who have radiological observations and/or inflammatory indicators associated with parallel infection, or who are immune deficient or severely hostile.

Remdesivir

Gilead Sciences, Inc. is developing a new nucleotide analogue prodrug as an experimental drug. It's an experimental antiviral treatment for Ebola and SARS. In a situation study on the original case of 2019-nCoV in the US, giving remdesivir for charitable practice on the 11th day next infection caused in lower virus lots in nasopharyngeal and oropharyngeal tests, as well as an improvement in the patient's clinical status. 9 However, randomized controlled trials are expected to judge the drug's safety and effectiveness in treating patients infected with the 2019-nCoV virus.

Convalescent therapies (plasma from recovered COVID-19 patients)

This technique has previously been used to aid passive immunisation. Convalescent plasma, interferon-beta/ribavirin mixture remedy, and lopinavir are among the therapeutic agents with possible advantages, according to MERS reports. 19 However, there is presently no COVID-19 experience or randomised organized clinical trials for this supervision.

Antiviral drugs

SARS disease was treated with lopinavir/ritonavir and ribavirin, with a positive clinical response. 20 Lopinavir and ribavirin

had *in vitro* antiviral action beside SARS related coronavirus at 48 hours at amounts of 4 and 50 g/mL, overall. Uncanny resemblance of exclusive implantations in the 2019-nCoV spike protein to HIV-1 gp120 and Gag was discovered in a recent study. 21 Would anti-HIV medications have an effect on the results of the 2019-nCoV dealing? More randomized precise trials in COVID-19 sufferer are needed.

Vaccine

Here is presently vaccine obtainable for preventing 2019-nCoV contagion. The many vaccines are now available for the use. In that India's-COVAXIN and COVISHIELD™, Pfizer's- Coronavirus vaccine.




Figure 3: Covid-19 Vaccines.

Directing the virus and the host response

Antivirals (e.g., remdesivir, favipiravir), antibodies (e.g., convalescent plasma, hyper immune immunoglobulins), anti-inflammatory agents (e.g., dexamethasone, statins), targeted immunomodulatory therapies (e.g., Sarilumab, Tocilizumab, Anakinra, Sarilumab, Ruxolitinib), anticoagulants (e.g., tyrosine kinase inhibitors). Dissimilar care modalities are expected to have diverse abilities at different levels of infection and with different disease symptoms. Early in the outbreak, viral inhibition should be more effective, whereas in hospitalised cases, viral inhibition should be more effective later [43,49] have stood began, but initial data from clinical trials in admitted sufferer with COVID-19 did not established strong advantage. anticoagulants might be beneficial to prevent thromboembolic difficulties.

Conclusions

COVID-19 is a live pandemic that is affecting people all over the world. Present treatment consists of reducing viral transmission and providing compassionate services for diseased patients in the lack of fundamental clinical treatments. By way of the occurrence of SARS-CoV-2 changes and novel research approaches get presented, we will want to continuously re-assess the essence of testing and outcome understanding.

Bibliography

1. Yang X., *et al.* "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". *The Lancet Respiratory Medicine* 8.5 (2020): 475-481.
2. February WHOJA. "Novel Coronavirus (2019-nCoV)". 7 (2020): 2020.
3. Organization WH. "Coronavirus disease 2019 (COVID-19): situation report" 82 (2020).
4. Fouchier RA., *et al.* "Koch's postulates fulfilled for SARS virus". *Nature* 423.6937 (2003): 240.
5. Perlman S. "Another decade, another coronavirus". *Massachusetts Medical Society* (2020).
6. Peiris JSM., *et al.* "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study". *Lancet* 361.9371 (2003): 1767-1772.
7. Zaki AM., *et al.* "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia". *The New England Journal of Medicine* 367.19 (2012): 1814-1820.
8. Chen N., *et al.* "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". *Lancet* 395.10223 (2020): 507-513.
9. Wu Z and McGoogan JMJJ. "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention". *JAMA* 323.13 (2020): 1239-1242.
10. Rate C-FJJPoM. "Characteristics of Patients Dying in Relation to COVID-19 in Italy Onder G, Rezza G, Brusaferro S". 23 (2020).
11. Zhou F., *et al.* "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". *Lancet* 395.10229 (2020): 1054-1062.
12. Du Y., *et al.* "Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study". *American Journal of Respiratory and Critical Care Medicine* 201.11 (2020): 1372-1379.
13. Gao Y., *et al.* "Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19". *Journal of Medical Virology* 10 (2020).
14. Livingston E and Bucher K. "Coronavirus disease 2019 (COVID-19) in Italy". *Journal* (2020).
15. Meyers C., *et al.* "Lowering the transmission and spread of human coronavirus". *Journal of Medical Virology* 93.3 (2021): 1605-1612.
16. Dong Y., *et al.* "Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China". *American Journal of Emergency Medicine* 145.6 (2020): e20200702.
17. Channappanavar R., *et al.* "T cell-mediated immune response to respiratory coronaviruses". 59.1 (2014): 118-128.
18. Rabi FA., *et al.* "SARS-CoV-2 and coronavirus disease 2019: what we know so far". *Pathogens* 9.3 (2020): 231.
19. Bosch BJ., *et al.* "The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex". *Journal of Virology* 77.16 (2003): 8801-8811.
20. Chen Y., *et al.* "Structure analysis of the receptor binding of 2019-nCoV". *Biochemical and Biophysical Research Communications* 525.1 (2020): 135-140.
21. Walls AC., *et al.* "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein". *Cell* 181.2 (2020): 281-292. e6.
22. Letko M., *et al.* "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". *Nature Microbiology* 5.4 (2020): 562-569.
23. Shu Z., *et al.* "Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases". *Frontiers in Medicine* (2020): 1-16.

24. Belouzard S., *et al.* "Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites". *106.14* (2009): 5871-5876.
25. Ou X., *et al.* "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV". *Nature Communications* 11.1 (2020): 1-12.
26. Belouzard S., *et al.* "Mechanisms of coronavirus cell entry mediated by the viral spike protein". *Viruses* 4.6 (2012): 1011-1033.
27. Hoffmann M., *et al.* "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor". *Cell* 181.2 (2020): 271-280.e8.
28. Shi J., *et al.* "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2". *Sciences* 368.6494 (2020): 1016-1020.
29. Hamming I., *et al.* "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis". *Journal of Pathology* 203.2 (2004): 631-637.
30. Jia HP, *et al.* "ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia". *Journal of Virology* 79.23 (2005): 14614-14621.
31. Yoshikawa T., *et al.* "Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells". *Journal of Virology* 83.7 (2009): 3039-3048.
32. Wang M., *et al.* "Thrombotic regulation from the endothelial cell perspectives". *Arteriosclerosis, Thrombosis, and Vascular Biology* 38.6 (2018): e90-e95.
33. Lovren F, *et al.* "Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis". *American Journal of Physiology-Heart and Circulatory Physiology* 295.4 (2008): H1377-H84.
34. Jung F, *et al.* "COVID-19 and the endothelium". (2020): 1-5.
35. Zeng H., *et al.* "Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection". *Journal of Virology* 86.2 (2012): 667-678.
36. Huang C., *et al.* "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". *Lancet* 395.10223 (2020): 497-506.
37. Alhazzani W., *et al.* "Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)". (2020): 1-34.
38. Vaira L., *et al.* "Anosmia and ageusia: common findings in COVID-19 patients". *Laryngoscope* (2020): 10.
39. Yan C., *et al.* "Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms". *International Forum of Allergy and Rhinology* (2020).
40. Lechien JR, *et al.* "Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter. European Study". *European Archives of Oto-Rhino-Laryngology* 277.8 (2020): 2251-2261.
41. Murray CJJM. "19 Health Service Utilization Forecasting Team, Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months". (2020).
42. Wang W., *et al.* "Detection of SARS-CoV-2 in different types of clinical specimens". *JAMA* 323.18 (2020): 1843-1844.
43. Mez J., *et al.* "Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football". *JAMA* 318.4 (2017): 360-370.
44. Namekar M., *et al.* "Evaluation of a new commercially available immunoglobulin M capture enzyme-linked immunosorbent assay for diagnosis of dengue virus infection". *Journal of Clinical Microbiology* 51.9 (2013): 3102-3106.
45. Sethuraman N., *et al.* "Interpreting diagnostic tests for SARS-CoV-2". *JAMA* 323.22 (2020): 2249-2251.

46. Guo G., *et al.* "Pressure-Transient Behavior for a Horizontal Well Intersecting Multiple Random Discrete Fractures". paper SPE.28390:25-8.
47. Bond K., *et al.* "Post-market validation of three serological assays for COVID-19". Melbourne, Australia: Doherty Institute (2020).
48. Calvet G., *et al.* "Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study". *The Lancet Infectious Diseases* 16.6 (2016): 653-660.
49. Alhazzani W., *et al.* "Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)". *Intensive Care Medicine* (2020): 1-34.